540
Participants
Start Date
August 18, 2023
Primary Completion Date
March 17, 2026
Study Completion Date
February 15, 2027
DS-3939a
One IV infusion Q3W on Day 1 of each 21-day cycle
RECRUITING
UZ Leuven, Leuven
RECRUITING
Hospital Universitari Vall D'Hebron, Barcelona
RECRUITING
Next Madrid, Pozuelo de Alarcón
RECRUITING
Institut Claudius Regaud, Toulouse
RECRUITING
Florida Cancer Specialists, Sarasota
RECRUITING
The Medical College of Wisconsin, INC, Milwaukee
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
University of Texas M.D. Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Institut Gustave Roussy, Villejuif
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Rhode Island Hospital, Providence
NOT_YET_RECRUITING
McGill University Health Center, Montreal
RECRUITING
Princess Margaret Cancer Center, Toronto
RECRUITING
National Cancer Center Hospital, Chūōku
RECRUITING
Kansai Medical University Hospital, Hirakata-shi
RECRUITING
National Cancer Center Hospital East, Kashiwa
RECRUITING
Cancer Institute Hospital of Jfcr, Kōtoku
RECRUITING
Kindai University Hospital, Ōsaka-sayama
NOT_YET_RECRUITING
Seoul National University Hospital, Seoul
NOT_YET_RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
NOT_YET_RECRUITING
Asan Medical Center, Seoul
NOT_YET_RECRUITING
Samsung Medical Center, Seoul
Lead Sponsor
Daiichi Sankyo
INDUSTRY